Targeting HTR2B suppresses non-functioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis.

Shaojian LinLiangbo WangChangxi HanYuting DaiChangsheng LiYanting LiuBo ZhangNing HuangAnke ZhangTao ZhangYu WangJing XieHao TangYijun ChengHong YaoMeiqing LouLi XueZhe Bao Wu

Published in: Neuro-oncology (2024)

HTR2B is a potential therapeutic target for NFPAs, and its inhibition could improve CAB efficacy. A dual therapy approach may be beneficial for NFPA patients with high HTR2B expression.

Keyphrases

signaling pathway
poor prognosis
cell proliferation
cancer therapy
stem cells
combination therapy
long non coding rna
climate change
replacement therapy
protein kinase